ClinicalTrials.gg
RecruitingNCT02860364TITAN:COMMENCEUpdated Nov 18, 2026

Comparing Hypothermic Temperatures During Hemiarch Surgery

An interventional study of Hypothermic circulatory arrest in Thoracic Aortic Disease, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2018; still recruiting 8 years 9 months later.
Updated Nov 18, 2026Site recruiting status changedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Hypothermic circulatory arrest is an important surgical technique, allowing complex aortic surgeries to be performed safely. Hypothermic circulatory arrest provides protection to cerebral and visceral organs, but may result in longer cardiopulmonary bypass times during surgery, increased risks of bleeding, inflammation, and neuronal injury. To manage these consequences, a trend towards warmer core body temperatures during circulatory arrest has emerged. This trial will randomize patients to either mild (32°C) or moderate (26°C) hypothermia during aortic hemiarch surgery to determine if mild hypothermia reduces the length of cardiopulmonary bypass time and other key measures of morbidity and mortality.

02

Conditions studied

  • Thoracic Aortic Disease

Browse trials for

03

In context

Aortic Diseases

109 studies on the registry are indexed under Aortic Diseases; 44 are open to participants now.

This study's planned enrollment of 328 is above the median of 93 across 43 interventional studies indexed under Aortic Diseases.

Browse Aortic Diseases studies →

Lead sponsor

Ottawa Heart Institute Research Corporation is the lead sponsor of 182 studies on the registry; 42 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Planned selective anterograde cerebral perfusion
  • Anticipated lower body arrest time of \< 20 minutes
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Surgery for aortic dissection or urgent/emergent operations
  • Total arch replacement
  • Known inability to perform selective anterograde cerebral perfusion (sACP)
  • Patients with known/documented coagulopathies
  • Patients with cold agglutinin disease or those that test positive on routine preop screening
  • Pre-existing severe neurological impairment or inability to accurately assess neurocognitive function as determined by the operating surgeon
  • Severe carotid disease

    1. Any patient with previously documented carotid stenosis of ≥ 70% (via Doppler US, MRA, or CTA) without neurological deficits
    2. Carotid stenosis ≥ 50% with neurological deficits
    3. Previous carotid endarterectomy or stenting
  • Patients in renal failure or currently being treated with renal replacement therapy (RRT) or estimated (eGFR) \< 30 ml/min/1.73m2
  • Use of an drug or device at time of enrollment
  • Participation in another clinical trial which interferes with performance of the study procedures or assessment of the outcomes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
328 participants (estimated)

Study arms

  • Experimental
    Mild Hypothermic Circulatory Arrest

    During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.

    Procedure: Hypothermic circulatory arrest

  • Active comparator
    Moderate Hypothermic Circulatory Arrest

    During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.

    Procedure: Hypothermic circulatory arrest

Interventions

  • ProcedureHypothermic circulatory arrest

    During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.

06

What researchers measure

Primary outcomes

  1. Hierarchical Composite of Mortality, Stroke, Transient Ischemic Attack, Acute Kidney Injury, and Perioperative Bleeding

    The primary endpoint is a hierarchical composite consisting of five clinical outcomes, prioritized in the following order: (1) mortality, (2) stroke, (3) transient ischemic attack (TIA), (4) acute kidney injury (AKI; KDIGO stage 1 or higher), and (5) perioperative bleeding (Class 2 or higher according to the Universal Definition of Perioperative Bleeding). The hierarchical composite endpoint will be analyzed using the Win Ratio.

    Time frame: Up to 90 days after surgery.

Secondary outcomes

  1. Rates of Neurologic Injury

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to incidence of neurologic injury, including transient ischemic attack (TIA) and permanent neurological dysfunction (PND) or stroke.

    Time frame: Up to 90 days after surgery.

  2. Incidence of Acute Kidney Injury (AKI)

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the incidence of acute kidney injury (AKI), defined as Stage 1 or greater using the KDIGO criteria. Using the KDIGO criteria, Stage 1 AKI is defined as an increase in serum creatinine of 1.5-1.9x the baseline or an increase \>= 27umol/L with urine output \<0.5mL/kg/hour for 6-12 hours.

    Time frame: Up to 90 days after surgery.

  3. Incidence of Delirium

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the incidence of delirium, using the Confusion Assessment Method (CAM). The Confusion Assessment Method defines delirium as the presence of acute changes in mental status with fluctuating course, plus inattention and the presence of either disorganized thinking OR altered level of consciousness.

    Time frame: Up to 90 days after surgery.

  4. Death

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the incidence of death

    Time frame: Up to 90 days after surgery.

  5. Evaluate differences in the duration of cardiopulmonary bypass used in patients who receive mild or moderate hypothermic circulatory arrest during aortic hemiarch surgery

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the length of time that the patient remains on cardiopulmonary bypass.

    Time frame: During the index procedure

  6. Rates of Mediastinal re-exploration for bleeding

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the rates of mediastinal re-exploration (re-operation) for bleeding.

    Time frame: Up to 90 days after surgery.

  7. Incidence and quantity of perioperative blood transfusions

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the number and quantity of perioperative blood transfusions

    Time frame: Up to 90 days after surgery.

  8. Incidence of prolonged Mechanical Ventilation

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the duration of mechanical ventilation. Mechanical ventilation will be defined as use of a mechanical ventilator ≥48 hours.

    Time frame: Up to 90 days after surgery.

  9. Perioperative Myocardial Infarction

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the incidence of perioperative myocardial infarction. This will be clinically diagnosed using a combination of electrocardiographic (new Q wave on 12 lead ECG) and/or biochemical (TnI \> 45 ng/L) markers.

    Time frame: Up to 48 hours after surgery.

  10. Length of Stay

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the duration of a patient's stay in the intensive care unit and on the hospital ward.

    Time frame: Up to 90 days after surgery.

  11. Quality of life (SF-12)

    Comparison of mild (32°C) vs moderate (26°C) hypothermia in aortic hemiarch surgery with respect to the patient's quality of life measured using the Short Form (SF) 12 questionnaire.

    Time frame: Up to 90 days after surgery.

  12. Incidence of Perioperative Bleeding (UDPB Class 2 or Higher)

    Comparison of mild (32°C) versus moderate (26°C) hypothermia during aortic hemiarch surgery with respect to the incidence of perioperative bleeding, defined as Class 2 or higher according to the Universal Definition of Perioperative Bleeding (UDPB). Assessment will include mediastinal re-exploration for bleeding or cardiac tamponade and postoperative chest tube output.

    Time frame: Up to 90 days after surgery.

07

Study locations

14 of 14 sites recruiting
08

References and documents

Publications

  • Jabagi H, Wells G, Boodhwani M. COMMENCE trial (Comparing hypOtherMic teMperaturEs duriNg hemiarCh surgEry): a randomized controlled trial of mild vs moderate hypothermia on patient outcomes in aortic hemiarch surgery with anterograde cerebral perfusion. Trials. 2019 Dec 9;20(1):691. doi: 10.1186/s13063-019-3713-9. PubMed 31815641 ↗

Individual participant data

Plan to share: No — Individual participant data will not be made available to other researchers.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2018 (actual). Primary completion is estimated for Dec 2030, 154 months after the start.

Of 21 interventional studies with no phase under Aortic Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 107. This study's planned 154 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2016
First posted
Aug 9, 2016
StartActual
Feb 20, 2018
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • University of British Columbia · Vancouver, CanadaNot yet recruiting→Recruiting
  • Dalhousie university · Halifax, CanadaNot yet recruiting→Recruiting
Show 2 added (2 Canada)
  • Horizon Health Network · Saint John, Canada
  • Newfoundland Health Services · St. John's, Canada
Nov 18, 2026
Enrollment
282→328
Nov 18, 2026
Eligibility
2 inclusion criteria edited, 1 removed; 4 exclusion criteria edited, 3 added
What changed in the criteria
Inclusion criteria
  • RemovedElective aortic hemiarch surgery
  • EditedPlanned unilateral selective anterograde cardioplegiacerebral perfusion
  • EditedAble to provide written informed consent
Exclusion criteria
  • EditedSurgery for acute aortic dissection or urgent/emergent operations
  • EditedInabilityKnown inability to perform unilateral selective anterograde cerebral perfusion (uSACPsACP)
  • EditedPatients with known/documented coagulopathycoagulopathies
  • AddedSevere carotid disease
  • EditedSevere carotid disease, defined as: anyAny patient with previously documented carotid stenosis of >≥ 70% (via Doppler ultrasound (US), magnetic resonance angiography (MRA), or computer tomography angiography (CTA)) without neurological deficits; or carotid stenosis > 50% with neurological deficits; or previous carotid endarterectomy or stenting
  • AddedCarotid stenosis ≥ 50% with neurological deficits
  • AddedPrevious carotid endarterectomy or stenting
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Composite endpoint of neurologic and acute kidney injuryNow Hierarchical Composite of Mortality, Stroke, Transient Ischemic Attack, Acute Kidney Injury, and Perioperative BleedingTime frame: Up to 90 days after surgery.
Nov 18, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence of Silent StrokesNow Incidence of Perioperative Bleeding (UDPB Class 2 or Higher)Time frame: Up to 90 days after surgery.
Nov 18, 2026
Contact
Study contact changed: a•••@ottawaheart.ca · •••7230→k•••@ottawaheart.ca. See the current contact
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    2 sites added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • University of British Columbia · Vancouver, CanadaNot yet recruiting→Recruiting
    • Dalhousie university · Halifax, CanadaNot yet recruiting→Recruiting
    Show 2 added (2 Canada)
    • Horizon Health Network · Saint John, Canada
    • Newfoundland Health Services · St. John's, Canada
    Enrollment 282→328
    Eligibility 2 inclusion criteria edited, 1 removed; 4 exclusion criteria edited, 3 added
    What changed in the criteria
    Inclusion criteria
    • RemovedElective aortic hemiarch surgery
    • EditedPlanned unilateral selective anterograde cardioplegiacerebral perfusion
    • EditedAble to provide written informed consent
    Exclusion criteria
    • EditedSurgery for acute aortic dissection or urgent/emergent operations
    • EditedInabilityKnown inability to perform unilateral selective anterograde cerebral perfusion (uSACPsACP)
    • EditedPatients with known/documented coagulopathycoagulopathies
    • AddedSevere carotid disease
    • EditedSevere carotid disease, defined as: anyAny patient with previously documented carotid stenosis of >≥ 70% (via Doppler ultrasound (US), magnetic resonance angiography (MRA), or computer tomography angiography (CTA)) without neurological deficits; or carotid stenosis > 50% with neurological deficits; or previous carotid endarterectomy or stenting
    • AddedCarotid stenosis ≥ 50% with neurological deficits
    • AddedPrevious carotid endarterectomy or stenting
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Composite endpoint of neurologic and acute kidney injuryNow Hierarchical Composite of Mortality, Stroke, Transient Ischemic Attack, Acute Kidney Injury, and Perioperative BleedingTime frame: Up to 90 days after surgery.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence of Silent StrokesNow Incidence of Perioperative Bleeding (UDPB Class 2 or Higher)Time frame: Up to 90 days after surgery.
    Contact Study contact changed: a•••@ottawaheart.ca · •••7230→k•••@ottawaheart.ca. See the current contact
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02860364
Responsible party
Sponsor
First posted
Aug 9, 2016
Start date
Feb 20, 2018
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Jehangir Appoo, MD
Contact
jappoo@ucalgary.ca
403-944-2515
Khatira Mehdiyeva
Contact
kmehdiyeva@ottawaheart.ca
Munir Boodhwani, MD
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion